Titlebook: Introduction to Antibody Engineering; Florian Rüker,Gordana Wozniak-Knopp Textbook 2021 Springer Nature Switzerland AG 2021 monoclonal ant

动作谜

专心

没有准备

Monoclonal Antibodies and Hybridomas,n 1975 Köhler and Milstein (Köhler G and Milstein C. Nature. 1975;256:495–7) under the title .. This paper is the foundation and one of the pillars of today’s modern antibody technology, documented by the fact that 6 monoclonal antibodies are among the top 10 best-selling drugs worldwide as of 2018

Antecedent

Antibody Display Systems,ke therapeutic antibodies with prescribed properties. Besides hybridoma technology, which is still state of the art for antibody hit discovery but that also has intrinsic limitations regarding throughput, several other promising methodologies emerged. All of these have in common that they couple the

Plaque

Transgenic Animals for the Generation of Human Antibodies,erived from transgenic animal platforms. In these platforms, the host antibody heavy chain VDJ and light chain VJ repertoire are substituted by their counterparts which are encoded exclusively by human transgenes. These platforms take advantage of the host’s naturally antigen-driven antibody selecti

压碎

送秋波

Bispecific Antibodies,ic reagents. Apart of performing two tasks in one, their inherently linked two specificities were found to be able to initiate novel biological effects, unpreceded in biological phenomena such as engaging effector cells to act against tumor cells, replacing a missing link in an enzyme cascade, or ac

拖债

,Antibody–Drug Conjugates,ecifically guides a cytotoxic agent to diseased cells while sparing healthy tissue, ultimately resulting in a drastically improved therapeutic index. This chapter describes the manifold aspects of ADCs, beginning with the history of ADCs from the first idea to key developments and drawbacks to the c

Nausea

Alternative Binding Scaffolds: Multipurpose Binders for Applications in Basic Research and Therapy,cades. In contrast to their hetero-tetrameric, macromolecular counterparts, these affinity reagents are based on non-antibody structures and provide several advantages, like a smaller size, improved biophysical properties as well as the possibility to engage difficult-to-address target proteins thro

陶器

Chimeric Antigen Receptor (CAR) Redirected T Cells,roducing complete and lasting remissions in patients with certain subtypes of so far refractory B cell malignancies. CAR T cells are derived from the patient’s own immune cells that are ex vivo genetically engineered with a CAR that binds a defined target and transmits an activation signal upon targ